Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 6 (June)

1. Brachytherapy partial breast irradiation: analyzing effect of source configurations on dose metrics relevant to toxicity.
   Int J Radiat Oncol Biol Phys, 71(3): 940-4. [Abstract] [Full-text]
2. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
   Int J Radiat Oncol Biol Phys, 71(3): 695-704. [Abstract] [Full-text]
3. Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer.
   Int J Radiat Oncol Biol Phys, 71(3): 689-94. [Abstract] [Full-text]
4. Malignant phyllodes tumor of the breast: local control rates with surgery alone.
   Int J Radiat Oncol Biol Phys, 71(3): 710-3. [Abstract] [Full-text]
5. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
   Int J Radiat Oncol Biol Phys, 71(3): 705-9. [Abstract] [Full-text]
6. Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan Breast Reconstruction Outcomes Study.
   Ann Surg, 247(6): 1019-28. [Abstract] [Full-text]
7. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
   Int J Cancer, 123(3): 577-85. [Abstract] [Full-text]
8. A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
   Int J Cancer, 123(3): 730-6. [Abstract] [Full-text]
9. Breast cancer screening: evidence for false reassurance?
   Int J Cancer, 123(3): 680-6. [Abstract] [Full-text]
10. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1.
    Int J Cancer, 123(3): 526-34. [Abstract] [Full-text]
11. Macrophages, more than just scavengers: their role in breast development and cancer.
    ANZ J Surg, 78(6): 432-6. [Abstract] [Full-text]
12. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    J Natl Cancer Inst, 100(11): 805-14. [Abstract] [Full-text]
13. Management of the axilla after the finding of a positive sentinel lymph node: a proposal for an evidence-based risk-adapted algorithm.
    Am J Clin Oncol, 31(3): 293-9. [Abstract] [Full-text]
14. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
    Am J Clin Oncol, 31(3): 250-4. [Abstract] [Full-text]
15. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Am J Clin Oncol, 31(3): 219-25. [Abstract] [Full-text]
16. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer.
    Gynecol Oncol, 109(3): 418-25. [Abstract] [Full-text]
17. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.
    J Clin Oncol, 26(17): 2813-20. [Abstract] [Full-text]
18. In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells.
    Biochem Biophys Res Commun, 372(1): 30-4. [Abstract] [Full-text]
19. Invited commentary: Postmenopausal unopposed estrogen and breast cancer risk in the Women's Health Initiative--before and beyond.
    Am J Epidemiol, 167(12): 1416-20. [Abstract] [Full-text]
20. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
    Am J Epidemiol, 167(12): 1407-15. [Abstract] [Full-text]
21. Are patients with skin cancer at lower risk of developing colorectal or breast cancer?
    Am J Epidemiol, 167(12): 1421-9. [Abstract] [Full-text]
22. Proteomic analysis of MCF-7 cells treated with benzo[a]pyrene, dibenzo[a,l]pyrene, coal tar extract, and diesel exhaust extract.
    Toxicology, 249(1): 1-10. [Abstract] [Full-text]
23. Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.
    Genes Chromosomes Cancer, 47(8): 680-96. [Abstract] [Full-text]
24. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
    BMC Genomics, 9: 239. [Abstract] [Full-text]
25. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.
    Cancer, 112(12): 2646-54. [Abstract] [Full-text]
26. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema.
    Cancer, 112(12): 2809-19. [Abstract] [Full-text]
27. Osteoblasts-derived TGF-beta1 enhance motility and integrin upregulation through Akt, ERK, and NF-kappaB-dependent pathway in human breast cancer cells.
    Mol Carcinog, 47(7): 526-37. [Abstract] [Full-text]
28. Breast cancer surgery: do all patients want to go to high-volume hospitals?
    Surgery, 143(6): 699-705. [Abstract] [Full-text]
29. Overall survival in women with breast cancer: the influence of pepsinogen C gene polymorphism.
    DNA Cell Biol, 27(6): 333-6. [Abstract] [Full-text]
30. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells.
    Biochem Biophys Res Commun, 372(3): 497-502. [Abstract] [Full-text]
31. Systemic endocrine instigation of indolent tumor growth requires osteopontin.
    Cell, 133(6): 994-1005. [Abstract] [Full-text]
32. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.
    J Biol Chem, 283(25): 17635-51. [Abstract] [Full-text]
33. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
    J Natl Cancer Inst, 100(12): 854-61. [Abstract] [Full-text]
34. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.
    J Natl Cancer Inst, 100(12): 898-905. [Abstract] [Full-text]
35. Mammography facility characteristics associated with interpretive accuracy of screening mammography.
    J Natl Cancer Inst, 100(12): 876-87. [Abstract] [Full-text]
36. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA.
    J Cell Biol, 181(6): 985-98. [Abstract] [Full-text]
37. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    BMC Cancer, 8: 165. [Abstract] [Full-text]
38. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Eur J Surg Oncol, 34(7): 746-55. [Abstract] [Full-text]
39. Interstitial laser thermotherapy (ILT) of breast cancer.
    Eur J Surg Oncol, 34(7): 739-45. [Abstract] [Full-text]
40. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
    Eur J Surg Oncol, 34(7): 734-8. [Abstract] [Full-text]
41. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.
    Br J Radiol, 81(967): 549-63. [Abstract] [Full-text]
42. Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo.
    BMC Cancer, 8: 160. [Abstract] [Full-text]
43. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.
    BMC Cancer, 8: 158. [Abstract] [Full-text]
44. Breast MRI in the evaluation of eligibility for accelerated partial breast irradiation.
    AJR Am J Roentgenol, 191(1): 272-7. [Abstract] [Full-text]
45. Sonographic and mammographic appearances of breast hemangioma.
    AJR Am J Roentgenol, 191(1): W17-22. [Abstract] [Full-text]
46. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma.
    Br J Surg, 95(7): 827-33. [Abstract] [Full-text]
47. Epidermal growth factor promotes breast cancer cell chemotaxis in CXCL12 gradients.
    Biotechnol Bioeng, 100(6): 1205-13. [Abstract] [Full-text]
48. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?
    J Clin Oncol, 26(18): 3073-82. [Abstract] [Full-text]
49. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.
    Am J Epidemiol, 168(1): 98-104. [Abstract] [Full-text]
50. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
    J Clin Oncol, 26(18): 3006-14. [Abstract] [Full-text]
51. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
    J Clin Oncol, 26(18): 2999-3005. [Abstract] [Full-text]
52. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women.
    Am J Epidemiol, 168(1): 49-57. [Abstract] [Full-text]
53. The effects of race and age on axillary lymph node involvement in breast cancer patients at a Midwestern safety-net hospital.
    Am J Surg, 196(1): 64-9. [Abstract] [Full-text]
54. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.
    Am J Surg, 196(1): 81-7. [Abstract] [Full-text]
55. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
    Radiology, 248(1): 79-87. [Abstract] [Full-text]
56. Finding early invasive breast cancers: a practical approach.
    Radiology, 248(1): 61-76. [Abstract] [Full-text]
57. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Hum Pathol, 39(7): 1096-102. [Abstract] [Full-text]
58. Keratin immunohistochemistry does not contribute to correct lymph node staging in patients with invasive lobular carcinoma.
    Hum Pathol, 39(7): 1011-7. [Abstract] [Full-text]
59. Procollagen I COOH-terminal fragment induces VEGF-A and CXCR4 expression in breast carcinoma cells.
    Exp Cell Res, 314(11): 2289-98. [Abstract] [Full-text]
60. Sensing estrogen's many pathways.
    ACS Chem Biol, 3(6): 338-40. [Abstract] [Full-text]
61. Primary breast lymphoma in a patient with silicone breast implants: a case report and review of the literature.
    J Plast Reconstr Aesthet Surg, 61(7): 822-5. [Abstract] [Full-text]
62. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy.
    Int J Cancer, 123(4): 967-71. [Abstract] [Full-text]
63. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.
    Int J Cancer, 123(4): 933-41. [Abstract] [Full-text]
64. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
    Int J Cancer, 123(4): 846-51. [Abstract] [Full-text]
65. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
    Int J Cancer, 123(4): 780-6. [Abstract] [Full-text]
66. Polygenes, risk prediction, and targeted prevention of breast cancer.
    N Engl J Med, 358(26): 2796-803. [Abstract] [Full-text]
67. Delayed breast reconstruction with implants after invasive breast cancer does not impair prognosis.
    Ann Plast Surg, 61(1): 11-8. [Abstract] [Full-text]
68. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Pathobiology, 75(4): 244-51. [Abstract] [Full-text]
69. Oncogenic role of DDX3 in breast cancer biogenesis.
    Oncogene, 27(28): 3912-22. [Abstract] [Full-text]
70. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain.
    Cancer Invest, 26(6): 615-23. [Abstract] [Full-text]
71. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
    Nat Genet, 40(7): 844-53. [Abstract] [Full-text]
72. Breast-conserving surgery using projection and reproduction techniques of surgical-position breast MRI in patients with ductal carcinoma in situ of the breast.
    J Am Coll Surg, 207(1): 62-8. [Abstract] [Full-text]
73. Use of reoperative sentinel lymph node biopsy in breast cancer patients.
    J Am Coll Surg, 207(1): 57-61. [Abstract] [Full-text]
74. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?
    Cancer, 113(1): 30-7. [Abstract] [Full-text]
75. Completion of adjuvant radiation therapy among women with breast cancer.
    Cancer, 113(1): 22-9. [Abstract] [Full-text]
76. Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database.
    Cancer, 113(1): 38-47. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.